---
schema_version: "secwatch.filing_event.v1"
accession: "0001447028-24-000066"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:03:34.020100+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arbutus and Moderna agree to extend patent trial schedule to Sept 2025

## Summary
- Arbutus, Genevant filed stipulation with Moderna extending case schedule in COVID-19 vaccine patent suit.
- Parties request trial start moved to September 24, 2025, subject to court approval.
- Lawsuit seeks damages for patent infringement in manufacture and sale of MRNA-1273.
- Stipulation cites need to accommodate outstanding discovery from Moderna and third parties.

## SEC filing metadata
- accession: 0001447028-24-000066
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000144702824000066/0001447028-24-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000144702824000066/abus-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447028-24-000066
- JSON: https://secwatch.observer/filing/0001447028-24-000066.json
- Plain text: https://secwatch.observer/filing/0001447028-24-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.